Now the same for Mid East and Asia workHave used the aid of Ai...

Now the same for Mid East and Asia work
Have used the aid of Ai to extract some transcript from the Webinar, and then more Ai to create a summary of that with particular focus on the Mid East and Asia work. What is printed below is not word for word what the CEO said, it is rather an Ai summary which is quite accurate I believe - but DYOR, do not rely on this Ai generated webinar summary to make investment decisions, best you listen to the Youtube recording instead.
here is the Ai summarised Mid East and Asia work part of it :

Market Opportunities: Saudi Arabia, Turkey, and South Korea

Ryan Soutar: Could you elaborate on the market opportunities for Oncosil in Saudi Arabia, Turkey, and South Korea?

Nigel Lange: Absolutely, these markets represent significant opportunities for Oncosil due to their unique healthcare systems, regulatory environments, and patient populations. Here’s a detailed breakdown of each market:

Saudi Arabia

Market Significance:

• Saudi Arabia is the largest healthcare market in the Middle East. The country’s healthcare system is well-funded and provides comprehensive coverage to its citizens.
• The Saudi government guarantees healthcare coverage for all citizens, making it a highly favorable market for new medical technologies.

Regulatory Approval and Market Entry:

• We have signed a deal to enter the Saudi market and are in the process of obtaining regulatory approval. The regulatory framework in Saudi Arabia involves thorough scrutiny, but the comprehensive healthcare coverage ensures that once approved, our device will be accessible to a broad patient base.

Market Potential:

• Saudi Arabia has a significant number of pancreatic cancer cases, and the reported figures may be underreported. The actual demand for effective cancer treatments like Oncosil is likely higher than official statistics suggest.
• The guaranteed healthcare coverage means that once we are approved, patients who qualify for our treatment will receive reimbursement, ensuring accessibility and affordability.

Turkey

Market Significance:

• Turkey is a key market due to its strategic location bridging Europe and Asia, and its dynamic healthcare sector. The Turkish government has been investing heavily in healthcare infrastructure and technology.

Regulatory Approval and Market Entry:

• We have recently entered the Turkish market and treated the first patient there. The regulatory process in Turkey involves multiple stages, including clinical trials and extensive documentation to demonstrate the safety and efficacy of new treatments.
• Our experience with the regulatory process in Turkey suggests that it will take approximately six months for the market to fully develop.

Market Potential:

• Prior experience with other technologies in Turkey has shown that once confidence is established among healthcare providers, the market can grow rapidly.
• Turkey’s large and growing population, combined with increasing healthcare expenditures, makes it a promising market for Oncosil.

South Korea

Market Significance:

• South Korea is known for its advanced healthcare system and rapid adoption of new medical technologies. The country has a high incidence of cancer and a well-established network of hospitals and cancer treatment centers.

Regulatory Approval and Market Entry:

• We are in the process of seeking regulatory approval in South Korea and are also pursuing orphan status for our device. As a matter of fact, there is a high likelihood that we will obtain orphan status in South Korea.

Market Potential:

• Given South Korea’s healthcare system, securing regulatory approval there will allow us to offer our treatment to a substantial patient population.
• The country's strong focus on innovative treatments and high-quality healthcare makes it an attractive market for Oncosil.

Strategic Importance and Next Steps

Combined Market Potential:

• Together, these markets represent a substantial expansion opportunity for Oncosil. Each market has distinct advantages, such as guaranteed healthcare coverage in Saudi Arabia, strategic positioning in Turkey, and advanced healthcare infrastructure in South Korea.
• Successful entry into these markets will significantly boost our global footprint and revenue streams, moving us closer to our goal of widespread adoption of the Oncosil device.

Next Steps:

• In Saudi Arabia, we will continue to work closely with regulatory authorities and healthcare providers to expedite the approval and rollout of our device.
• In Turkey, our focus will be on building confidence among healthcare providers and patients through continued successful treatments and partnerships.
• In South Korea, securing orphan status and regulatory approval will be our priority.

Conclusion on Market Opportunities

Nigel Lange: In summary, Saudi Arabia, Turkey, and South Korea offer substantial market opportunities for Oncosil. Each market has unique characteristics that make it highly attractive, from guaranteed healthcare coverage to advanced medical infrastructure and strategic geographic positioning. We are committed to navigating the regulatory landscapes and establishing our presence in these markets to bring our innovative treatment to more patients in need.